A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus
NCT ID: NCT07073170
Last Updated: 2025-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1
36 participants
INTERVENTIONAL
2025-07-25
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of LY3549492 in Japanese Participants With Type 2 Diabetes Mellitus (T2D) and Healthy Japanese Participants
NCT06869018
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
NCT05086445
A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus
NCT05596747
A Study of LY3549492 in Participants With Type 2 Diabetes Mellitus (T2DM)
NCT05327595
A Study of LY2922470 in Healthy Participants and Participants With Diabetes
NCT01746017
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LY3549492 Dose 1
Participants will receive LY3549492 orally
LY3549492
Administered orally
LY3549492 Dose 2
Participants will receive LY3549492 orally
LY3549492
Administered orally
LY3549492 Dose 3
Participants will receive LY3549492 orally
LY3549492
Administered orally
Placebo
Participants will receive Placebo orally
Placebo
Administered orally
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LY3549492
Administered orally
Placebo
Administered orally
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have type 2 diabetes for at least 6 months
* Have been treated with diet and exercise, with or without a stable dose of metformin for at least 3 months
* Have hemoglobin A1c (HbA1c) of at least 7% and no greater than 10%
* Have a body mass index (BMI) of at least 20 milligrams per square meter (kg/m2) and no greater than 40 kg/m2
* Have had a stable body weight for the 3 months prior to screening
* Women must not be of childbearing potential
Exclusion Criteria
* Have had an episode of severe hypoglycemia within 6 months or have a history of hypoglycemia unawareness
* Have a clinically significant gastric emptying abnormality
* Have or have a history of pancreatitis
* Have signs and symptoms of liver disease, with the exception of non-alcoholic fatty liver disease
* Have a personal or family history of multiple endocrine neoplasia syndrome type 2 or medullary thyroid carcinoma
* Have an uncontrolled endocrine abnormality
* Have an abnormal blood pressure or pulse rate
* Have a 12-lead electrocardiogram (ECG) abnormality
* Have a significant history within the past 6 months or current evidence of comorbidities capable of altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Role: STUDY_DIRECTOR
Eli Lilly and Company
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Peking University People's Hospital
Beijing, , China
West China Hospital of Sichuan University
Chengdu, , China
Peking University First Hospital
Dongcheng District, , China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Role: CONTACT
Physicians interested in becoming principal investigators please contact
Role: CONTACT
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
J3H-GH-GZNH
Identifier Type: OTHER
Identifier Source: secondary_id
27335
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.